The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
Open accessAbstract
BACKGROUND: Inclisiran inhibits hepatic synthesis of proprotein convertase subtilisin-kexin type 9. Previous studies suggest that inclisiran might provide sustained reductions in low-density lipoprotein (LDL) cholesterol levels with infrequent dosing. METHODS: We enrolled patients with atherosclerotic cardiovascular disease (ORION-10 trial) and patients with atherosclerotic cardiovascular disease or an atherosclerotic cardiovascular disease risk equivalent (ORION-11 trial) who had elevated LDL cholesterol levels despite receiving statin therapy at the maximum tolerated dose. Patients were randomly assigned in a 1:1 ratio to receive either inclisiran (284 mg) or placebo, administered by subcutaneous injection on day 1, day 90, and every 6 months thereafter over a period of 540 days. The coprimary end points in each trial were the placebo-corrected percentage change in LDL cholesterol level from baseline to day 510 and the time-adjusted percentage change in LDL cholesterol level from baseline after day 90 and up to day 540. RESULTS: A total of 1561 and 1617 patients underwent randomization in the ORION-10 and ORION-11 trials, respectively. Mean (±SD) LDL cholesterol levels at baseline were 104.7±38.3 mg per deciliter (2.71±0.99 mmol per liter) and 105.5±39.1 mg per deciliter (2.73±1.01 mmol per liter), respectively. At day 510, inclisiran reduced LDL cholesterol levels by 52.3% (95% confidence interval [CI], 48.8 to 55.7) in the ORION-10 trial and by 49.9% (95% CI, 46.6 to 53.1) in the ORION-11 trial, with corresponding time-adjusted reductions of 53.8% (95% CI, 51.3 to 56.2) and 49.2% (95% CI, 46.8 to 51.6) (P<0.001 for all comparisons vs. placebo). Adverse events were generally similar in the inclisiran and placebo groups in each trial, although injection-site adverse events were more frequent with inclisiran than with placebo (2.6% vs. 0.9% in the ORION-10 trial and 4.7% vs. 0.5% in the ORION-11 trial); such reactions were generally mild, and none were severe or persistent. CONCLUSIONS: Reductions in LDL cholesterol levels of approximately 50% were obtained with inclisiran, administered subcutaneously every 6 months. More injection-site adverse events occurred with inclisiran than with placebo. (Funded by the Medicines Company; ORION-10 and ORION-11 ClinicalTrials.gov numbers, NCT03399370 and NCT03400800.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Randomized controlled trials, including the VICTORION-Mono and VICTORION-Difference trials, as well as ORION -10, -11, and other Phase III trials, have consistently demonstrated that inclisiran reduces LDL-C compared with placebo in primary and secondary prevention settings.5, 6, 7”
From Small Interfering RNA for LDL-Cholesterol Reduction (2026) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The trials showed that patients achieved LDL-C decreases of 52.3% and 49.9% at Day 510 [44].”
From Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management (2026) · cites this paper as [44]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The ORION-10 and ORION-11 trials achieved LDL-C reductions greater than 50% among their participants [44].”
From Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management (2026) · cites this paper as [44]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The initial injections of inclisiran at Day 1 and 90 followed by biannual maintenance resulted in a long-term average LDL-C reduction of − 44% to − 48% across ORION-1 and ORION-10 and ORION-11 [25, 44].”
From Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management (2026) · cites this paper as [44]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical observations demonstrate that numerous patients stop taking their daily statin medications or PCSK9 antibody injections irregularly which reduces their ability to prevent cardiovascular diseases [44, 80].”
From Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management (2026) · cites this paper as [44]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Accordingly, PCSK9 siRNA and monoclonal antibodies blocking the PCSK9/LDLR interaction potently lower LDL cholesterol and reduce the risk of adverse cardiovascular events (Sabatine et al., 2017; Schwartz et al., 2018; Ray et al., 2020).”
From PCSK9 deficiency alters brain lipid composition without affecting brain development and function (2023) · cites this paper as Ray et al., 2020
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Accordingly, PCSK9 inhibitory antibodies and siRNA potently reduce LDL cholesterol to unprecedented low levels and are approved for treatment of hypercholesterolemia.”
From PCSK9 deficiency alters brain lipid composition without affecting brain development and function (2023) · cites this paper as Ray et al., 2020
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“targeted PCSK9 inhibition restores hepatic LDLR levels, decreases plasma LDL-C levels and improves cardiovascular outcomes.7,9–11”
From Sirtuin-1 directly binds and deacetylates hepatic PCSK9 thereby promoting the inhibition of LDL receptor degradation (2025) · cites this paper as [11]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The phase 3 ORION-10 and ORION-11 trials evaluated inclisiran compared with placebo across a total of 1561 and 1617 patients with atherosclerosis or an atherosclerotic CVD risk-equivalent, respectively [137]. Compared with placebo, inclisiran reduced LDL-C levels by − 52% and − 50%, respectively.”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [137]
The cited source says what the claim attributes to it.
In the citing paper
“In addition to monoclonal antibodies that sequester PCSK9 in the circulation and are now prescribed to patients, the small-interfering RNA inclisiran that targets PCSK9 hepatic production has recently been approved, following reports of substantial LDL lowering [50% reduction (95% confidence interval 47–53)] with this drug (11).”
From PCSK9 and the nervous system: a no-brainer? (2023) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“In addition to the monoclonal antibodies, an siRNA, inclisiran, which also targets PSCK9, has demonstrated the ability to reduce LDL cholesterol by 49-52% in trials evaluating individuals with established cardiovascular disease or ASCVD risk equivalent (129).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [129]
The cited source says what the claim attributes to it.
In the citing paper
“In addition to the monoclonal antibodies, an siRNA, inclisiran, which also targets PSCK9 and is referred to as a PCSK9 siRNA in this section, has demonstrated the ability to reduce LDL cholesterol by 49–52% in trials evaluating individuals with established CVD or ASCVD risk equivalent (123).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [123]
The cited source says what the claim attributes to it.
In the citing paper
“Inclisiran was noted to decrease LDL by ∼50% in the ORION trials [20]”
From Oral PCSK9 inhibitors for elevated LDL-C: A systematic review and meta-analysis of randomized trials (2026) · cites this paper as [20]
The cited source says what the claim attributes to it.
In the citing paper
“The analysis of 11 RCTs for quantitative synthesis included more than 13,000 participants showed inclisiran produces significant LDL-C reduction versus placebo treatment [24, 25, 38–44, 46, 49].”
The cited source says what the claim attributes to it.
In the citing paper
“Large-scale research including well-powered trials such as ORION 10 and ORION 11 demonstrates that Inclisiran shows strong potential as a potent lipid-lowering agent [44].”
In the citing paper
“Patients on statins with high LDL-C levels and ASCVD or at least one ASCVD risk equivalent were included in the two phase 3 trials ORION-10 and ORION-11 (Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol), and obtained a further 50% reduction of LDL-C with inclisiran.278”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [278]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Self-citationEvolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801174 · Cited by 3,634
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.003 · Cited by 2,691
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
Ray, K. K., Landmesser, U., Leiter, L. A., Kallend, D., Dufour, R., Karakas, M., Hall, T., Troquay, R. P. T., Turner, T., Visseren, F. L. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615758 · Cited by 992
Self-citationRodríguez, F., Maron, D. J., Knowles, J. W., Virani, S. S., Lin, S., & Heidenreich, P. A. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2018.4936 · Cited by 347
The Implications of Therapeutic Complexity on Adherence to Cardiovascular Medications
Choudhry, N. K., Fischer, M. A., Avorn, J., Liberman, J. N., Schneeweiß, S., Pakes, J., Brennan, T. A., & Shrank, W. H. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.495 · Cited by 314
Cited by
Sorted by citations
Items 601–700 of 1,007
Dutta, S., Shah, R., Singhal, S., Singh, S., Piparva, K. G., & Katoch, C. D. S. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2293201 · Cited by 12
Kulkarni, S., Watts, M., & Kostapanos, M. S. (2024) · BMJ · doi:10.1136/bmj-2022-072584 · Cited by 12
Bhatia, S. N., & Dahlman, J. E. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2315789121 · Cited by 12
An Update on Dyslipidemia Management and Medications: A Review
Taher, Z. A., Taher, A. A., & Radi, S. (2024) · Cureus · doi:10.7759/cureus.56255 · Cited by 16
Manzato, M., Meeusen, J. W., Donato, L. J., Jaffe, A. S., & Vasile, V. C. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100886 · Cited by 11
Mansoor, T., Rao, B. H., Gupta, K., Parikh, S. S., Abramov, D., Mehta, A., Al Rifai, M., Virani, S. S., Nambi, V., Minhas, A. M. K., et al. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00712-x · Cited by 12
Jiang, Y., Wang, Y., Ma, S., Qian, L., Jing, Y., Chen, X., & Yang, J. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1415668 · Cited by 16
Challenges in achieving LDL cholesterol targets and novel approaches to lipid lowering
Malick, W. A., Choi, D., Langsted, A., Bittner, V., Nordestgaard, B. G., Stroes, E. S. G., & Rosenson, R. S. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf123 · Cited by 14
Jia, X., Rifai, M. A., Liu, J., Agarwala, A., Gulati, M., & Virani, S. S. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00856-6 · Cited by 12
Novel therapies for familial hypercholesterolemia
Mohamed, F., Seedat, F., & Raal, F. J. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000590 · Cited by 13
Self-citationTombling, B. J., Lammi, C., Bollati, C., Anoldi, A., Craik, D. J., & Wang, C. K. L. (2021) · ChemBioChem · doi:10.1002/cbic.202100103 · Cited by 12
Therapeutic application of genome editing in dyslipidemia
Whittaker, M. N., & Musunuru, K. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000805 · Cited by 12
Achieving lipid targets within 12 months of an acute coronary syndrome: an observational analysis
Alsadat, N., Hyun, K. K., Boroumand, F., Juergens, C., Kritharides, L., & Brieger, D. B. (2022) · The Medical Journal of Australia · doi:10.5694/mja2.51442 · Cited by 12
Drug Treatment of Hypercholesterolemia in Older Adults: Focus on Newer Agents
Stoll, F., Eidam, A., Michael, L., Bauer, J. M., & Haefeli, W. E. (2022) · Drugs & Aging · doi:10.1007/s40266-022-00928-z · Cited by 13
Optimal cardiovascular medical therapy: current guidelines and new developments
Reed, S., Dhir, N., & Widmer, R. J. (2022) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2022.2083903 · Cited by 12
Lipoprotein(a) in Cardiovascular Diseases: Insight From a Bibliometric Study
Šuran, D., Vošner, H. B., Završnik, J., Kokol, P., Sinkovič, A., Kanič, V., Kokol, M., Naji, F. H., & Završnik, T. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.923797 · Cited by 14
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition: The Big Step Forward in Lipid Control
Rikhi, R. R., & Shapiro, M. D. (2023) · European Cardiology Review · doi:10.15420/ecr.2023.14 · Cited by 13
Addison, M., Ranasinghe, P. D., & Webb, D. J. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2277330 · Cited by 14
Agboola, F., Lin, G. A., Kazi, D. S., McKenna, A., & Pearson, S. D. (2021) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2021.27.7.961 · Cited by 12
Pharmacotherapy in familial hypercholesterolemia - Current state and emerging paradigms
Kallapur, A. S., & Sallam, T. (2021) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2021.12.011 · Cited by 14
Efficacy and Safety of PCSK9 Monoclonal Antibodies in Patients With Diabetes
Marouf, B. H., Iqbal, Z., Mohamad, J. B., Bashir, B., Schofield, J. D., Syed, A. A., Kilpatrick, E. S., Stefanutti, C., & Soran, H. (2022) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.12.005 · Cited by 12
Chan, Y., & Ramji, D. P. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-1924-7_2 · Cited by 13
Li, J., Lei, X., Li, Z., & Yang, X. (2023) · Medicine · doi:10.1097/md.0000000000032728 · Cited by 12
Update on the impact of lipid and glucose control on diabetic wound healing
Rui, S., Xu, Y., Ji, Z., Li, X., Tao, Z., Luo, W., Yao, Y., Chen, L., & Ma, G. (2025) · Metabolism Open · doi:10.1016/j.metop.2025.100408 · Cited by 12
Atherogenic dyslipidaemia and residual cardiovascular risk: Understanding the link to heart disease
Girón, G. O., Otero, S., Nikolaou, P., Alcover, S., Ramos-Regalado, L., Zaragoza, C., Liberale, L., Borrell-Pagés, M., Padró, T., Suades, R., et al. (2026) · European Journal of Clinical Investigation · doi:10.1111/eci.70167 · Cited by 12
Chronic In Vivo CRISPR-Cas Genome Editing: Challenges, Long-Term Safety, and Outlook
Bao, C., Channell, C. I., Tseng, Y.-H., Bailey, J., Sbaiti, N., Demirkol, A., & Tsang, S. H. (2026) · Cells · doi:10.3390/cells15020156 · Cited by 14
Shaharyar, M. A., Bhowmik, R., Al-Abbasi, F. A., AlGhamdi, S. A., Alghamdi, A. M., Sarkar, A., Kazmi, I. A., & Karmakar, S. (2023) · Vaccines · doi:10.3390/vaccines11020241 · Cited by 12
RNAi-mediated rheostat for dynamic control of AAV-delivered transgenes
Subramanian, M. P., McIninch, J., Zlatev, I., Schlegel, M. K., Kaittanis, C., Nguyen, T. M., Agarwal, S., Racie, T., Alvarado, M. A., Wassarman, K., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37774-5 · Cited by 11
Synthesis of a Complex and Highly Potent PCSK9 Inhibitor
Kuethe, J. T., Lee, J., Thaisrivongs, D. A., Yasuda, N., Pollack, S. R., Leone, J. F., DaSilva, J., Biba, M., Tsay, F., Regalado, E. L., et al. (2023) · Organic Letters · doi:10.1021/acs.orglett.3c01635 · Cited by 11
Giglio, R. V., Muzurović, E. M., Patti, A. M., Toth, P. P., Agarwal, M. A., Almahmeed, W. A., Klisic, A. N., Ciaccio, M., & Rizzo, M. (2023) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484231186855 · Cited by 11
Lipoprotein(a) and calcific aortic valve disease: current evidence and future directions
Lan, N. S. R., Khan, Z. U., & Watts, G. F. (2023) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000976 · Cited by 11
Li, Q., Yin, K., Ma, H., Liu, H.-H., Li, S., Luo, X., Hu, R., Zhang, W., Lv, Z.-S., Niu, X.-L., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.01.008 · Cited by 15
Webb, D. J. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae140 · Cited by 12
A guide to RNA structure analysis and RNA ‐targeting methods
Aguilar, R., Mardones, C., Moreno, A. A., & Cepeda‐Plaza, M. (2024) · FEBS Journal · doi:10.1111/febs.17368 · Cited by 14
Achieving More Optimal Lipid Control with Non-Statin Lipid Lowering Therapy
Nicholls, S. J., & Nelson, A. J. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01280-4 · Cited by 12
Morton, J. I., Liew, D., Watts, G. F., Zoungas, S., Nicholls, S. J., Dixon, P., & Ademi, Z. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf114 · Cited by 11
Inclisiran: Efficacy in Real World—Systematic Review and Meta-Analysis
Rodrigo-Alaíz, Á., Corral-Gudino, L., de Isla, L. P., Pardo, H. G., Calle, D. G., & Miramontes‐González, J. P. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14124163 · Cited by 14
Jianu, N., Nițu, E.-T., Merlan, C., Nour, A., Buda, S., Suciu, M., Luca, S. A., Sbârcea, L., Andor, M., & Buda, V. O. (2025) · Pharmaceuticals · doi:10.3390/ph18081150 · Cited by 14
Nițu, E.-T., Jianu, N., Merlan, C., Foica, D., Sbârcea, L., Buda, V. O., Suciu, M., Lombrea, A., & Man, D. E. (2025) · Life · doi:10.3390/life15081185 · Cited by 18
Zhao, Y., Goto, M., Vaziri, N. D., Khazaeli, M., Liu, H., Farahanchi, N., Khanifar, E., Farzaneh, T., Haslett, P. A. J., Moradi, H., et al. (2020) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.000257 · Cited by 11
Lipoprotein(a): Insights for the Practicing Clinician
Telyuk, P., Austin, D., Luvai, A., & Zaman, A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11133673 · Cited by 12
Novel Gene-Correction-Based Therapeutic Modalities for Monogenic Liver Disorders
Ghasemzad, M., Hashemi, M., Miri-Lavasani, Z., Hossein‐Khannazer, N., Bakhshandeh, H., Gramignoli, R., Alikhani, H. K., Najimi, M., Nikeghbalian, S., & Vosough, M. (2022) · Bioengineering · doi:10.3390/bioengineering9080392 · Cited by 11
Association of PCSK9 Loss-of-Function Variants With Risk of Heart Failure
Trudsø, L. C., Ghouse, J., Ahlberg, G., Bundgaard, H., & OLESEN, M. S. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.4798 · Cited by 10
Milosavljević, M. N., Stefanović, S., & Pejčić, A. V. (2023) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001429 · Cited by 11
Gioscia, R., Castagno, C., Verdoia, M., Conti, B., Forliti, E., & Rognoni, A. (2023) · World Journal of Cardiology · doi:10.4330/wjc.v15.i4.142 · Cited by 12
Cowart, K., Singleton, J., & Carris, N. W. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.06.011 · Cited by 11
The Link between miRNAs and PCKS9 in Atherosclerosis
Mačvanin, M., Gluvic, Z. M., Klisic, A. N., Manojlovic, M. S., Suri, J. S., Rizzo, M., & Isenović, E. R. (2023) · Current Medicinal Chemistry · doi:10.2174/0109298673262124231102042914 · Cited by 13
Novel therapeutic targets and agents for pediatric dyslipidemia
Sunil, B., Foster, C., Wilson, D. P., & Ashraf, A. P. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188211058323 · Cited by 13
Zyryanov, S. K., & Butranova, O. I. (2022) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2022-5271 · Cited by 10
Lp(a) - an overlooked risk factor
Laffin, L. J., & Nissen, S. E. (2023) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2023.01.003 · Cited by 12
Research advances in current drugs targeting hyperlipidemia (Review)
Zhao, H., Wang, Y., Li, Y., Cheng, R., & Chen, W. (2025) · Molecular Medicine Reports · doi:10.3892/mmr.2025.13623 · Cited by 11
Faggiano, A., Maloberti, A., Ambrosetti, M., Giallauria, F., Mureddu, G., Venturini, E., Ruzzolini, M., Maranta, F., Vatri, M., Zadre, L., et al. (2026) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2025.11.010 · Cited by 10
Important Aspects of siRNA Design for Optimal Efficacy In Vitro and In Vivo
Bhakta-Yadav, M. S., & Brown, T. L. (2025) · International Journal of Cell Biology · doi:10.1155/ijcb/6663816 · Cited by 11
Personalized Medicine in Lipid-Modifying Therapy
Tomlinson, B., Lin, C.-H., Chan, P., & Lam, C. W. K. (2021) · Personalized Medicine · doi:10.2217/pme-2020-0110 · Cited by 11
Secondary Prevention after Myocardial Infarction: What to Do and Where to Do It
Tuka, V., Holub, J., & Bělohlávek, J. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2306210 · Cited by 13
Primary prevention of cardiovascular disease in women
Gray, M. P., Vogel, B., Mehran, R., Leopold, J. A., & Figtree, G. A. (2024) · Climacteric · doi:10.1080/13697137.2023.2282685 · Cited by 11
Shuai, Q., Xie, W., Chen, S., Su, H., & Yan, Y. (2024) · Journal of Materials Chemistry B · doi:10.1039/d3tb02876c · Cited by 10
Huang, H. Y. R., Badar, S. M., Said, M. T., Shah, S., Bharadwaj, H. R., Ramamoorthy, K., Alrawashdeh, M. M., Haroon, F., Basit, J., Saeed, S., et al. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-09457-x · Cited by 10
Cheng, Q., Sun, J., Zhong, H., Wang, Z., Liu, C., Zhou, S., & Deng, J. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1393333 · Cited by 15
Chen, C., Wei, F., Dong, Y., & Liu, C. (2024) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-024-07587-9 · Cited by 10
Rosoff, D. B., Wagner, J., Jung, J., Pacher, P., Christodoulides, C., Davey Smith, G., Ray, D., & Lohoff, F. W. (2025) · Diabetes · doi:10.2337/db24-0451 · Cited by 10
Devisetty, U. K., Neef, E. D., Gordon, E. R. L., Zapata, V. V., Narva, K. E., Mézin, L., Cahon, P. M., Witwer, K. W., & Sridharan, K. (2024) · Computational Toxicology · doi:10.1016/j.comtox.2024.100340 · Cited by 10
Ho, V. Q. T., Tran, N. B., Nguyen, N. M. T., Arrighini, G. S., Downes, D., Dandamudi, M., Ferrara, V. Z., Ho, T. H. Q., Walia, H., Barbagelata, A., et al. (2025) · Open Heart · doi:10.1136/openhrt-2025-003490 · Cited by 11
Obesity phenotypes and atherogenic dyslipidemias
Choe, H. J., Almas, T., Neeland, I. J., Lim, S. K., & Després, J. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70151 · Cited by 14
Inclisiran – a new era in lipid-lowering therapy
Voevoda, M. I., Gurevich, V. S., Владиславович, Е. М., & Сергиенко, И. В. (2022) · Kardiologiia · doi:10.18087/cardio.2022.6.n2115 · Cited by 10
Li, Z.-F., & Wu, N. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.911429 · Cited by 11
MicroRNAs: emerging biomarkers and therapeutic targets of bone fragility in chronic kidney disease
Smout, D., Craenenbroeck, A. H. V., Jørgensen, H. S., & Evenepoel, P. (2022) · Clinical Kidney Journal · doi:10.1093/ckj/sfac219 · Cited by 10
Shapiro, M. D., Taub, P. R., Louie, M. J., Lei, L., & Ballantyne, C. M. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.06.973 · Cited by 12
Nonstatin therapy to reduce low-density lipoprotein cholesterol and improve cardiovascular outcomes
Singh, A., & Cho, L. S. (2024) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.91a.23058 · Cited by 12
Inclisiran siRNA technology in the management of dyslipidemia: A narrative review of clinical trials
Olatunji, G. D., Kokori, E., Yusuf, I. A., Akinmoju, O. D., Egbunu, E. O., Muogbo, I., Lema, K. F., Kanagala, S. G., Owolabi, S., Muili, A. O., et al. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102419 · Cited by 10
Zrnić-Ćirić, M., Ostojić, M., Baralić, I., Kotur‐Stevuljević, J., Djordjevic, B. I., Markovic, S., Živković, S., & Stanković, I. (2021) · Nutrients · doi:10.3390/nu13030903 · Cited by 10
Towards Personalized Therapy of Aortic Stenosis
Mazur, P. K., Kopytek, M., Ząbczyk, M., Undas, A., & Natorska, J. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11121292 · Cited by 10
Tsushima, T., Tsushima, Y., Sullivan, C., & Hatipoğlu, B. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.12.011 · Cited by 9
Insights from ORION studies: focus on inclisiran safety
Catapano, A. L., Pirillo, A., & Norata, G. D. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa139 · Cited by 10
Agarwal, K., Lok, J. B., & Gane, E. J. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.08.020 · Cited by 10
An update on inclisiran for the treatment of elevated LDL cholesterol
Barkas, F., & Ray, K. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2337253 · Cited by 9
Self-citationBibliometric analysis of residual cardiovascular risk: trends and frontiers
Wang, L., Wang, S., Song, C., Yu, Y., Jiang, Y., Wang, Y., & Li, X. (2023) · Journal of Health Population and Nutrition · doi:10.1186/s41043-023-00478-z · Cited by 11
Afzal, Z., Cao, H., Chaudhary, M. A., Chigurupati, H. D., Neppala, S., Alruwaili, W., Awad, M. A., Sandesara, D., Siddique, M., Farman, A., et al. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102586 · Cited by 9
Delgado‐Lista, J., Mostaza, J. M., Arrobas-Velilla, T., Blanco‐Vaca, F., Masana, L., Pedro‐Botet, J., Pérez‐Martínez, P., Civeira, F., Cuende, J. I., Gómez-Barrado, J. J., et al. (2024) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2024.07.008 · Cited by 9
Vivas, D., Escobar, C., Cordero, A., Fernández-Olmo, R., Oterino, A., Blanco-Echevarría, A., Botana, M., Escribano, D., Freijo, M. D. M., Losas, P. M., et al. (2024) · REC CardioClinics · doi:10.1016/j.rccl.2024.06.002 · Cited by 10
Identification of selective and non-selective C9ORF72 targeting in vivo active siRNAs
Gilbert, J. W., Kennedy, Z., Godinho, B. M. D. C., Summers, A., Weiss, A., Echeverria, D., Bramato, B. M., McHugh, N., Cooper, D., Yamada, K., et al. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102291 · Cited by 8
Cheng, Z., Gao, M., Liu, Y., Yan, W., Zhang, Z., Jiao, N., & Li, C. (2024) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2024.10.017 · Cited by 11
Hu, J., Lei, H. C., Chen, J., Liu, L., Gui, Y., Sun, K., & Xu, D. (2024) · Journal of sport and health science/Journal of Sport and Health Science · doi:10.1016/j.jshs.2024.101007 · Cited by 9
Angleró-Rodríguez, Y., Lempp, F. A., Subramanian, M. P., McIninch, J., Schlegel, M. K., Bohan, D., Wong, E. Y. M., Brown, C. R., Foster, D. J., Castoreno, A. B., et al. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae1195 · Cited by 10
CRISPR-Cas9 Targeting PCSK9: A Promising Therapeutic Approach for Atherosclerosis
Gu, B., Li, M., Li, D., & Huang, K. (2025) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-024-10587-7 · Cited by 13
Basit, J., Ahmed, M., Singh, P., Ahsan, A., Zulfiqar, E., Iqbal, J., Fatima, M., Upreti, P., Hamza, M., & Alraies, M. C. (2025) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70039 · Cited by 10
Efficacy and safety of inclisiran based on background lipid-lowering treatment
Landmesser, U., Köenig, W., Leiter, L. A., Raal, F. J., Ray, K. K., Schwartz, G. G., Han, J., Conde, L. G., & Wright, R. S. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf214 · Cited by 9
Self-citationBurnett, H. F., Cichewicz, A. B., Natani, H., Bhowmik, D., Buesch, K., Fahrbach, K. R., Reichelt, A., Neupane, B., Pierre, V. J., & Jindal, R. (2025) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001712 · Cited by 10
Gene therapy for cardiac arrhythmias
Bains, S., Giudicessi, J. R., Odening, K. E., & Ackerman, M. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01168-5 · Cited by 10
Inverted chimeric RNAi molecules synergistically cotarget MYC and KRAS in KRAS-driven cancers
Chareddy, Y. S., Huggins, H. P., Sahoo, S. S., Stanland, L. J., Gutierrez-Ford, C., Whately, K. M., Edatt, L., Azam, S. H., Fleming, M. C., Im, J., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci187204 · Cited by 11
Chronic Coronary Artery Disease
Kittleson, M. M. (2025) · Annals of Internal Medicine · doi:10.7326/annals-25-03512 · Cited by 10
Oxidized Phospholipids, Lipoprotein(a), and Cardiovascular Outcomes After Acute Coronary Syndrome
Tsimikas, S., Szarek, M. J., Cobbaert, C. M., Romijn, F. P. H. T. M., Jukema, J. W., Bhatt, D. L., Bittner, V., Díaz, R., Fazio, S., Garon, G., et al. (2025) · Circulation · doi:10.1161/circulationaha.125.073855 · Cited by 9
Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose – 2025
Rached, F. H., Miname, M. H., Rocha, V. Z., Zimerman, A., Cesena, F. Y., Sposito, A. C., Santos, R. D., Behr, P. E. B., Bianco, H. T., Alves, R. J., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250640 · Cited by 42
Molecular Mechanisms Underlying Atherosclerosis and Current Advances in Targeted Therapeutics
Zhu, B. J. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27020634 · Cited by 11
Zhang, H., Xu, Q., Ye, M., Wu, X., Ren, Z., Qin, L., Tang, Z., Wang, G., Xiang, Q., & Liu, L. (2026) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2026.01.045 · Cited by 9
Epidemiology of cardiovascular–kidney–metabolic syndrome
Mavromatis, L. A., & Grams, M. E. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-026-01078-w · Cited by 12
Tomlinson, B., Chan, P., Zhang, Y., & Lam, C. W. K. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1801638 · Cited by 11
Pharmacogenomics of statins and familial hypercholesterolemia
Chora, J. R., & Bourbon, M. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000746 · Cited by 10
RNA interference-based therapies for the control of atherosclerosis risk factors
Kettunen, S., Ruotsalainen, A., & Ylä‐Herttuala, S. (2022) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000972 · Cited by 10
Dixon, D. L., & Saseen, J. J. (2020) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2020.12.009 · Cited by 9
Metadata
- Authors
- Ray, K. K., Wright, R. S., Kallend, D., Koenig, W., Leiter, L. A., Raal, F. J., Bisch, J. A., Richardson, T., Jaros, M., Wijngaard, P. L. J., & Kastelein, J. J. P.
- Affiliations
- Mayo Clinic (US)
- From the Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College London, London (K.K.R.); the Department of Cardiology, Mayo Clinic, Rochester, MN (R.S.W.); the Medicines Company, Zurich, Switzerland (D.K.); Deutsches Herzzentrum München, Technische Universität München, and Deutsches Zentrum für Herz-Kreislauf-Forschung (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Munich, and the Institute of...
- St. Michael's Hospital (CA)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-04-16
- Volume
- 382
- Issue
- 16
- Pages
- 1507-1519
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3012265841
- Semantic Scholar
- 0c86cfdc39f60ff6dc8854a281c1b95f32bdc692
- Cited by
- 1,665
- References
- 19
- Citations by year
- 2026: 296 · 2025: 290 · 2024: 289 · 2023: 273 · 2022: 231 · 2021: 193 · 2020: 87
- FWCI
- 183.81
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- The Medicines Company
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- inclisiran, PCSK9 inhibition, LDL cholesterol lowering, atherosclerotic cardiovascular disease, statin therapy, injection-site adverse events, hypercholesterolemia, lipid-lowering therapy, adverse events, drug safety and efficacy
- MeSH terms
- Proprotein Convertase 9, PCSK9 Inhibitors, Aged, Aged, 80 and over, Anticholesteremic Agents, Cardiovascular Diseases, Coronary Artery Disease, Double-Blind Method, Drug Administration Schedule, Female, Humans, Hypercholesterolemia, Injections, Subcutaneous, Cholesterol, LDL, Liver Function Tests, Male, Middle Aged, Risk Factors, Hydroxymethylglutaryl-CoA Reductase Inhibitors, RNA, Small Interfering
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
